DexCom Tops Q4 EPS and Sales Estimates, Affirms $5.16–5.25B 2026 Revenue Guide
DexCom posted Q4 EPS of $0.68, topping estimates by $0.03, on revenue of $1.26 billion versus $1.25 billion forecast. U.S. revenue rose 11% and international sales grew 18% year-over-year as the company reaffirmed its fiscal 2026 revenue guidance of $5.16–5.25 billion.
1. Q4 Financial Performance
DexCom delivered Q4 earnings per share of $0.68, beating the consensus by $0.03, on quarterly revenue of $1.26 billion versus the $1.25 billion estimate. U.S. revenue increased 11% year-over-year while international sales expanded 18%, reflecting broad-based demand across regions.
2. Fiscal 2026 Guidance
The company reaffirmed its full-year 2026 revenue outlook at $5.16 billion to $5.25 billion, underscoring management’s confidence in sustained market penetration and product adoption throughout the fiscal year.